OakChart

Avalo Therapeutics Inc

AVTXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 11:01 AM ET

8.34+1.18 (16.48%)
2026-11-11 17:01 CET
Market cap
414.01 USD m
Revenue, TTM
0.06 USD m
Net income, TTM
-88.65 USD m
Free cash flow, TTM
-63.47 USD m
EPS diluted, TTM
-2.90
P/E
-
Compare

Price

AVTX against its 20, 50 and 200-day averages
2050200beatmiss
10.0015.0020.0013.1M26.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AVTXclose 8.3420-day 8.3550-day 12.78200-day 15.708.3452w low

65.6% under the 52-week high of 24.27 on 7 May 2026. 52-week low 6.53 on 23 Oct 2026. Last 15 sessions, 43.2% high to low

Profile

AVTX
52-week range, 10% of the way up
6.5324.27

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

IndexRUT
Employees33
IPONov 13, 2015
Beta0.74
ATR, 14d0.86
Rel volume1.07
Short float17.20%
Insider own10.39%
Inst own120.49%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap482.24M
Enterprise Value91.21M
Income-88.65M
Sales0.06M
Book/sh8.10
Cash/sh6.80
Dividend Est.0.01 (0.14%)
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees33
IPONov 13, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S8037.35
P/B1.03
P/C1.23
P/FCF-
EV/EBITDA-
EV/Sales1520.18
Quick Ratio16.63
Current Ratio16.63
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.90
EPS next Y-2.45
EPS next Q-0.46
EPS this Y57.26%
EPS next Y1.78%
EPS next 5Y26.30%
EPS past 3/5Y82.35% 70.20%
Sales past 3/5Y-85.16% -61.19%
EPS Y/Y TTM66.84%
Sales Y/Y TTM-69.27%
EPS Q/Q84.27%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.42.21% -

Ownership

Insider Own10.39%
Insider Trans-2.04%
Inst Own120.49%
Inst Trans80.60%
ROA-29.23%
ROE-33.57%
ROIC-20.22%
Gross Margin-15.25%
Oper. Margin-161961.02%
Profit Margin-150259.32%
SMA20-0.17%
SMA50-34.74%
SMA200-46.87%
Trades-

Technical

Shs Outstand53.92M
Shs Float51.81M
Short Float17.20%
Short Ratio5.39
Short Interest8.91M
52W High24.27 -65.64%
52W Low6.53 27.72%
Volatility8.92% 9.65%
ATR (14)0.86
RSI (14)40.97
Beta0.74
Rel Volume1.07
Avg Volume1.65M
Volume480,608

Performance

Perf Week17.96%
Perf Month-30.56%
Perf Quarter-57.12%
Perf Half Y-57.98%
Perf YTD-54.07%
Perf Year-46.19%
Perf 3Y-61.56%
Perf 5Y-99.87%
Perf 10Y-99.94%
Recom1.29
Target Price34.36
Prev Close7.16
Price8.34
Change %16.48%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 23, 2026DowngradeHH.C. WainwrightBuy → Neutral
Oct 23, 2026DowngradeGGuggenheimBuy → Neutral
Jul 06, 2026InitiatedLLeerink PartnersOutperform$38+355.6%
Jun 12, 2026InitiatedBBofA SecuritiesBuy$35+319.7%
Apr 09, 2026InitiatedWWolfe ResearchOutperform$48+475.5%
Apr 06, 2026InitiatedCCitizensMkt Outperform$52+523.5%
Feb 02, 2026InitiatedGGuggenheimBuy$50+499.5%
Dec 18, 2025InitiatedMMizuhoOutperform$39+367.6%
Sep 17, 2025ReiteratedHH.C. WainwrightBuy$15 → $25+199.8%
Sep 05, 2025InitiatedTTD CowenBuy

Peers

Mkt cap
TickerCompanyMkt cap
MLTXMoonLake Immunotherapeutics1.13B
ALMSAlumis Inc876.40M
ACRSAclaris Therapeutics Inc670.14M
ANABAnaptysBio Inc1.46B
UPBUpstream Bio Inc187.15M
ZURAZura Bio Ltd143.53M
ATTOAttovia Therapeutics Inc778.48M
EVMNEvommune Inc315.38M
TRAXFirst Tracks Biotherapeutics Inc2.16B
IFRXInflaRx NV176.85M

Insider trading

latest 14 of 62
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Sullivan Christopher RyanChief Financial OfficerSep 16 '26Option Exercise9.8812,394122,45352,294Sep 18 04:10 PM
Sullivan Christopher RyanChief Financial OfficerSep 16 '26Sale16.3312,394202,43739,900Sep 18 04:10 PM
Sullivan Christopher RyanChief Financial OfficerSep 10 '26Option Exercise8.0410,18581,88750,085Sep 11 04:10 PM
Sullivan Christopher RyanChief Financial OfficerSep 10 '26Sale17.6210,185179,45739,900Sep 11 04:10 PM
Doyle MittieChief Medical OfficerAug 28 '26Option Exercise8.046795,45952,455Sep 01 04:38 PM
Doyle MittieChief Medical OfficerAug 28 '26Sale20.0067913,58051,776Sep 01 04:38 PM
Sullivan Christopher RyanChief Financial OfficerAug 17 '26Option Exercise9.8840,821403,31181,594Aug 19 04:10 PM
Sullivan Christopher RyanChief Financial OfficerAug 18 '26Option Exercise9.8831,031306,58670,931Aug 19 04:10 PM
Sullivan Christopher RyanChief Financial OfficerAug 17 '26Sale19.8641,694828,09639,900Aug 19 04:10 PM
Sullivan Christopher RyanChief Financial OfficerAug 18 '26Sale20.0531,031622,32439,900Aug 19 04:10 PM
Doyle MittieChief Medical OfficerAug 17 '26Option Exercise12.651,00012,65052,776Aug 19 04:10 PM
Doyle MittieChief Medical OfficerAug 17 '26Sale20.001,00020,00051,776Aug 19 04:10 PM
CHRISTOPHER RYAN SULLIVANOfficerAug 18 '26Proposed Sale20.0531,031622,221Aug 18 04:18 PM
MITTIE DOYLEOfficerAug 17 '26Proposed Sale19.595,03798,675Aug 17 04:49 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 206
  • Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates (GlobeNewswire) -6.22%
  • Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress (GlobeNewswire) -7.33%
  • Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Loading…
  • Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates (GlobeNewswire)
  • Avalo Therapeutics to Participate in the BTIG Biotechnology Conference (GlobeNewswire)
  • Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum (GlobeNewswire)
  • Avalo Therapeutics to Join the Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
  • Avalo Therapeutics Appoints Ron Philip to Board of Directors (GlobeNewswire)
  • Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1ß Antibody (GlobeNewswire)
  • Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.340-0.588-0.3400.000.0012
2026Q22026-08-06-0.830-0.583-0.8340.000.0011
2026Q12026-05-13-0.980-1.025-0.9760.000.009
2025Q42026-03-23-0.766-1.459-0.7410.060.0010
2025Q32025-11-06-2.190-1.658-2.1870.000.008
2025Q22025-08-07-1.920-1.402-1.9170.000.007
2025Q12025-05-12-1.250-1.332-1.2510.000.005
2024Q42025-03-20-0.630-0.168-3.3750.200.006
2024Q32024-11-07-2.830-1.190-2.8340.250.002
2024Q22024-08-12-14.070-6.700-14.0710.000.001
2024Q12024-05-13-141-1.180-141.140.000.001
2023Q42024-03-29-10.100-4.800-10.1880.570.301
2023Q32023-11-09-26.400-264-26.8320.241.001
2023Q22023-08-03-141.6-192-140.730.641.002
2023Q12023-05-04-204-232.8-203.810.481.001
2022Q42023-03-29-237.6-175.99-249.970.903.613

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-806.4-1,066-1,3416.7517.76
2020FY-2,506-2,275-2,4866.705.20
2021FY-2,390-2,258-2,3895.406.08
2022FY-1,063-698.4-1,06318.0520.80
2023FY-114-96.000-113.581.921.70
2024FY-20.910-18.447-20.9090.440.18
2025FY-5.840-6.712-5.8400.060.00
2026FY--2.496--0.00
2027FY--2.452--0.00
2028FY--2.338--0.00
2029FY--2.598--0.00
2030FY--1.710--102.19

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-057000.000.000.00
2026Q4S2026-10-307000.000.000.00
2026Q4S2026-09-048000.000.000.00
2026Q4S2026-08-079000.000.000.00
2026Q4S2026-08-068000.000.000.00
2026Q4S2026-07-027000.000.000.00
2026Q4S2026-05-136000.000.000.00
2026Q4S2026-04-026000.000.000.00
2026Q4S2026-03-235000.000.000.00
2026Q4S2026-01-305000.000.000.00
2026Q4S2026-01-064000.000.000.00
2026Q4S2025-12-163000.000.000.00
2026Q4S2025-12-142000.000.000.00
2026Q4S2025-11-113000.000.000.00

Estimate history

EPS, annual1201.104-3454.502-1341.418-2485.584-2388.73-1062.65-113.579-20.909-5.838-2.8953
Period201720182019202020212022202320242025TTM
EPS, quarterly-2.834-3.375-1.251-1.917-2.187-0.741-0.976-0.834-0.344
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual27.8137.0286.756.6995.39818.0511.9240.4410.0590.06
Period201720182019202020212022202320242025TTM
Sales, quarterly0.2490.1920000.059000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0110.0140.0150.0260.0390.0390.80210.47218.51353.923
Period201720182019202020212022202320242025MRQ
Shares, quarterly9.68210.47210.82810.83717.82818.51324.63852.90153.923
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.060.060.441.9218.055.406.706.757.03
Cost of Goods Sold Incl. D&A0.070.34-0.201.283.473.042.042.495.09
Gross Profit-0.01-0.280.640.6414.582.364.664.261.94
Selling, General and Administrative Excl. Other95.5572.6441.5124.0852.0284.4951.9523.2516.64
Research and Development65.7850.0824.4413.7831.3159.8432.1911.765.79
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-95.56-72.92-40.87-23.44-37.44-82.13-47.29-18.99-14.70
Interest Expense---3.424.172.39-0.000.00
Unusual Expense1.739.52-2.544.630.000.0020.34-2.9120.65
Net Income Before Taxes-88.49-78.09-35.02-31.53-41.63-84.55-67.18-15.99-35.32
Income Taxes0.170.170.110.010.03-0.20-2.790.28-0.05
Consolidated Net Income-88.65-78.26-35.13-31.54-41.66-84.35-64.38-16.27-36.93
Net Income From Continuing Operations-88.65-78.26-35.13-31.54-41.66-84.35-64.38-16.27-36.93
Net Income-88.65-78.26-35.13-31.54-41.66-82.85-57.56-19.97-41.71
EPS (Recurring)-1.59-5.34-21.15-101.92-1,062.65-2,388.72-1,870.67-1,478.06-2,257.34
EPS (Basic, Before Extraordinaries)-2.90-5.84-7.94-113.58-1,062.65-2,388.73-2,485.58-1,341.42-3,454.50
EPS (Diluted)-2.90-5.84-20.91-113.58-1,062.65-2,388.73-2,485.58-1,341.42-3,454.50
EBITDA-95.49-72.58-40.70-23.29-37.27-80.48-45.45-17.54-12.85
Non-Operating Income (Expense)8.804.353.31-0.04-0.02-0.020.460.100.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.00-1.66
Stock Option Compensation Expense14.7010.764.622.754.985.974.952.212.29
Price To Sales Ratio14,306.374,125.96126.301.312.6331.4626.2834.2415.98
Gross Margin-15.25-483.05144.6733.2680.7743.7069.5363.0827.59
Operating Margin-161,961.02-123,601.69-9,267.80-1,218.50-207.41-1,521.56-706.02-281.37-209.21
Net Margin-150,259.32-132,642.37-7,965.76-1,639.50-230.78-1,534.81-859.22-295.86-593.45
Shares Outstanding53.9218.5110.470.800.040.040.030.020.01
Market Capitalization414.01414.0177.747.2947.45191.75198.01237.74131.80

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.060.000.000.000.19
Cost of Goods Sold Incl. D&A0.020.020.020.020.060.130.140.09
Gross Profit-0.02-0.02-0.020.04-0.06-0.13-0.140.10
Selling, General and Administrative Excl. Other23.3831.5020.8819.7919.1419.1814.5313.42
Research and Development15.0523.4214.0513.2713.6214.079.128.18
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-23.40-31.52-20.90-19.74-19.20-19.32-14.67-13.31
Unusual Expense-0.217.58-0.48-5.1612.532.53-0.3823.13
Net Income Before Taxes-18.94-36.34-19.62-13.59-30.61-20.75-13.14-35.23
Income Taxes0.010.020.010.130.010.020.010.11
Consolidated Net Income-18.95-36.36-19.63-13.72-30.62-20.77-13.15-35.34
Net Income From Continuing Operations-18.95-36.36-19.63-13.72-30.62-20.77-13.15-35.34
Net Income-18.95-36.36-19.63-13.72-30.62-20.77-13.15-35.34
EPS (Recurring)-0.35-0.71-0.99-0.94-1.56-1.75-1.28-1.83
EPS (Basic, Before Extraordinaries)-0.34-0.83-0.98-0.74-2.19-1.92-1.25-3.37
EPS (Diluted)-0.34-0.83-0.98-0.74-2.19-1.92-1.25-3.37
EBITDA-23.38-31.50-20.88-19.73-19.14-19.18-14.53-13.24
Non-Operating Income (Expense)4.252.760.800.991.111.101.151.22
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.124.192.823.562.492.152.562.29
Price To Sales Ratio14,306.3713,657.055,088.075,698.16926.80122.54190.98176.43
Gross Margin---72.88---54.69
Operating Margin----33,461.02----6,932.81
Net Margin----23,254.24----18,405.73
Shares Outstanding53.9252.9024.6418.5117.8310.8410.8310.47
Market Capitalization414.01971.41340.23329.31167.1754.0385.4877.74

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments98.37134.567.4213.1954.6418.9611.2610.672.47
Short Term Receivables0.000.610.141.924.804.395.246.087.43
Inventories0.000.000.000.020.040.000.020.320.38
Other Current Assets6.913.710.841.292.372.661.204.860.70
Total Current Assets105.29138.898.3916.4261.8426.0117.7221.9310.99
Net Property, Plant & Equipment0.461.211.972.412.691.611.450.590.04
Total Investments and Advances0.210.130.130.130.230.150.100.080.13
Intangible Assets10.5010.5010.5014.4114.4515.9916.8418.1731.96
Deferred Tax Assets1.25------0.09-
Other Assets0.000.000.000.001.000.000.0029.480.00
Total Assets117.70150.7320.9933.3780.2143.7636.1170.2543.12
Short Term Debt Incl. Current Port. of LT Debt0.390.570.546.460.480.430.160.000.00
Accounts Payable0.140.280.452.883.372.572.081.451.30
Income Tax Payable----0.000.000.552.032.26
Other Current Liabilities12.416.113.6312.7716.0312.239.3822.747.85
Total Current Liabilities12.946.964.6222.1119.8915.2212.1626.2211.41
Long Term Debt2.042.353.3717.2036.853.041.110.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities1.680.270.150.140.110.090.090.070.01
Other Liabilities18.008.125.554.830.280.841.7523.063.85
Total Liabilities34.6517.7013.6944.2857.1319.1915.1149.3415.26
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity83.05133.037.30-10.9123.0824.5620.9920.9027.86
Total Shareholders Equity83.05133.037.30-10.9123.0824.5621.0020.9127.86
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity83.05133.037.30-10.9123.0824.5621.0020.9127.86
Total Liabilities & Stockholders Equity117.70150.7320.9933.3780.2143.7636.1170.2543.12
Book Value Per Share4.4912.709.11-277.78589.36943.071,362.171,475.492,566.15
Tangible Book Value Per Share3.9211.70-3.99-644.48220.48328.92269.76192.72-377.39
Full-Time Employees332319204432186438
Price to Book Ratio0.883.410.50-23.408.318.0613.056.303.77
Return on Assets-58.31-40.91-116.06-73.35-136.08-161.23-30.57-65.1531.79
Return on Equity-72.43-50.06--684.77-354.08-282.65-77.66-151.4655.38
Return on Invested Capital-91.98-25.95-295.63-663.13-140.74-230.07-108.73-199.5027.90
Quick Ratio8.1419.961.820.743.111.711.460.820.93
Current Ratio8.1419.961.820.743.111.711.460.840.96

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-88.65-78.26-35.13-31.54-41.66-84.38-63.50-16.07-40.05
Depreciation0.070.340.170.160.171.661.841.461.85
Other Funds (Non Cash)14.0922.45-9.509.9314.778.9725.365.4526.36
Funds from Operations-74.33-55.30-44.35-21.44-26.69-73.73-36.10-9.14-11.86
Extraordinary Item0.000.000.000.000.000.000.00-7.960.00
Changes in Working Capital10.863.84-4.71-9.24-0.062.84-4.44-2.038.73
Income Taxes Payable----0.000.000.29-1.48-0.23
Cash from Operating Activities-63.47-51.46-49.06-30.68-26.75-70.89-40.54-19.13-3.13
Capital Expenditures0.000.000.00-0.16-0.10-0.11-0.06-0.26-0.56
Net Assets From Acquisitions0.000.000.000.000.000.00-1.640.00-1E-06
Sale of Fixed Assets and Businesses0.000.000.360.030.000.0012.843.961.43
Purchase or Sale of Investments-313.25-81.720.000.000.000.000.000.000.00
Purchase of Investments-447.71-113.720.000.000.000.000.000.000.00
Sale Or Maturity of Investments134.4632.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.00-4.140.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-313.25-81.720.36-0.13-0.10-0.1111.13-0.440.87
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock415.6215.10185.0746.290.1173.8644.8813.7310.70
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock415.6215.10185.0746.290.1173.8644.8813.7310.70
Proceedsfrom Stock Options404.9114.30115.6246.220.1172.3044.7612.903.93
Issuance or Reduction of Debt, Net0.000.000.00-21.24-14.8132.900.00-0.260.00
Change in Long Term Debt0.000.000.00-21.24-14.8132.900.00-0.260.00
Issuance of Long Term Debt0.000.000.000.000.0032.900.000.000.00
Reduction of Long Term Debt0.000.000.00-21.24-14.810.000.00-0.260.00
Net Financing Active Other Cash Flow-0.78-0.51-9.220.000.000.00-0.09-0.92-0.29
Other Financing Activities Uses-0.78-0.51-9.220.000.000.00-0.09-0.92-0.29
Cash from Financing Activities414.8414.59175.8525.04-14.70106.7644.7812.5610.40
Net Change in Cash38.12-118.59127.15-5.77-41.5535.7615.38-7.028.14
Free Cash Flow-63.47-51.46-49.06-30.84-26.85-71.00-40.60-19.40-3.69
Preferred Dividends (Cash Flow)-0.000.000.000.00----
Deferred Taxes & Investment Tax Credit-0.170.110.010.030.020.200.02-0.02

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments393.18400.3282.1498.37111.71113.28
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets7.567.616.686.912.141.90
Total Current Assets400.74407.9388.83105.29113.85115.19
Net Property, Plant & Equipment0.200.290.380.460.540.69
Total Investments and Advances70.0072.060.180.210.210.21
Intangible Assets10.5010.5010.5010.5010.5010.50
Deferred Tax Assets---1.25--
Other Assets0.000.000.000.000.000.00
Total Assets481.43490.7899.89117.70125.10126.58
Short Term Debt Incl. Current Port. of LT Debt0.150.240.330.390.440.48
Accounts Payable2.463.350.360.140.472.37
Other Current Liabilities21.4817.5410.9112.417.066.41
Total Current Liabilities24.0921.1311.6012.947.979.26
Long Term Debt2.002.002.002.042.122.20
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.470.460.451.680.300.29
Other Liabilities18.3218.5317.5218.0023.1610.26
Total Liabilities44.8842.1231.5734.6533.5522.01
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity436.55448.6668.3283.0591.55104.57
Total Shareholders Equity436.55448.6668.3283.0591.55104.57
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity436.55448.6668.3283.0591.55104.57
Total Liabilities & Stockholders Equity481.43490.7899.89117.70125.10126.58
Book Value Per Share8.108.482.774.495.149.65
Tangible Book Value Per Share7.908.282.353.924.558.68
Full-Time Employees---33--
Price to Book Ratio0.886.663.333.541.320.44
Return on Assets-29.23-32.50-71.09-58.31-89.35-39.35
Return on Equity-33.57-36.27-88.76-72.43-174.79-90.25
Return on Invested Capital-4.32-8.07-27.92-16.13-32.70-19.45
Quick Ratio16.6319.317.668.1414.2812.44
Current Ratio16.6319.317.668.1414.2812.44

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-18.95-36.36-19.63-13.72-30.62-20.77
Depreciation0.020.020.020.020.060.13
Other Funds (Non Cash)4.297.662.99-0.8515.345.61
Funds from Operations-14.63-28.67-16.61-14.42-15.22-15.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital3.088.68-1.080.18-1.153.61
Cash from Operating Activities-11.54-19.99-17.69-14.25-16.36-11.39
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-11.23-329.9325.502.40-13.26-70.86
Purchase of Investments-74.81-353.800.00-19.10-23.76-70.86
Sale Or Maturity of Investments63.5823.8825.5021.5010.500.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-11.23-329.9325.502.40-13.26-70.86
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.54410.212.180.6914.370.04
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.54410.212.180.6914.370.04
Proceedsfrom Stock Options0.00404.980.00-0.0714.330.04
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.780.00-0.00-0.51
Other Financing Activities Uses0.000.00-0.780.00-0.00-0.51
Cash from Financing Activities2.54410.211.400.6914.37-0.47
Net Change in Cash-20.2360.309.21-11.16-15.26-82.72
Free Cash Flow-11.54-19.99-17.69-14.25-16.36-11.39

Revenue breakdown

Product2024: 441.00K
Total Pharmaceutical Preparations revenue2025: 59.00K
United States2024: 441.00K 2025: 59.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3017.20%8.9M51.8M1.52M
2026-10-1524.89%12.0M48.1M941.31K
2026-09-3023.73%11.4M48.1M984.16K
2026-09-1526.90%12.9M48.1M1.23M
2026-08-3125.77%12.4M48.1M1.29M
2026-08-1427.29%13.1M48.0M1.41M
2026-07-3126.52%13.0M48.8M1.99M
2026-07-1526.33%12.7M48.2M1.98M
2026-06-3025.73%12.3M47.8M1.91M
2026-06-1515.50%7.4M47.8M1.57M
2026-05-2913.34%6.4M47.9M1.48M
2026-05-1513.47%6.3M46.4M1.34M
2026-04-3023.84%5.7M24.1M697.48K
2026-04-1526.97%5.2M19.4M644.39K
2026-03-3128.35%5.5M19.6M550.23K
2026-03-1325.75%4.1M15.9M438.39K
2026-02-2723.19%3.7M15.9M374.04K
2026-02-1322.65%3.6M15.9M351.66K
2026-01-3020.21%3.2M15.8M344.78K
2026-01-1518.92%3.0M15.8M354.03K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.503.606.4013.798.6494.000.000.982-0.0150.001
call5.001.103.702.203.56310.000.000.960-0.0130.001
call7.500.651.300.601.6121,1902.000.690-0.0530.005
call10.000.001.700.053.55258.000.000.484-0.1030.005
call12.500.001.701.524.13521.000.000.374-0.1120.005
call15.000.001.700.055.3306,3430.000.393-0.1500.005
call17.500.000.050.152.8061,2890.000.043-0.0160.001
call20.000.000.050.053.1236100.000.040-0.0160.001
call22.500.000.100.053.3963210.000.038-0.0170.001
call25.000.000.050.053.63451.000.000.036-0.0170.001
call30.000.000.050.054.0352340.000.033-0.0180.001
call35.000.000.050.054.36412.000.000.031-0.0190.001
put2.500.000.050.605.39547.000.00-0.051-0.0340.001
put5.000.000.050.112.88394.000.00-0.094-0.0340.002
put7.500.000.650.982.06514.000.00-0.310-0.0530.005
put10.001.404.900.807.40812.000.00-0.516-0.1020.005
put12.503.606.403.706.46027.000.00-0.625-0.1090.005
put15.005.608.902.557.20913.000.00-0.606-0.1480.005
put17.508.8011.003.487.05438.000.00-0.957-0.0150.001
put20.0010.5013.902.958.29930.000.00-0.961-0.0150.001
put22.5013.0016.406.408.71318.000.00-0.964-0.0150.001
put25.0015.5018.908.539.0722.000.00-0.966-0.0160.001
put30.0020.5023.9010.909.6670.000.00-0.969-0.0160.001
put35.0025.5028.900.0010.1510.000.00-0.971-0.0160.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-06SCHEDULE 13G/ASEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-05S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-11-05424B5SEC
2026-11-05SCHEDULE 13G/ASEC
2026-10-29SCHEDULE 13GSEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900381.89K2
2026-08001.55M6
2026-070020.00K1
2026-060026.10K1
2026-05005.28M8
2026-0400575.55K6
2026-0300411.61K1
2026-020000
2026-010000
2025-120000
2025-1100162.94K1

Institutional holders

Manager% owned
FMR LLC9.79%
BlackRock, Inc.8.30%
Nantahala Capital Management, LLC7.09%
Deep Track Capital, LP6.87%
Caligan Partners LP6.02%
TCG Crossover Management, LLC5.74%
Affinity Asset Advisors, LLC5.52%
STATE STREET CORP5.50%
FARALLON CAPITAL MANAGEMENT, L.L.C.4.75%
Point72 Asset Management, L.P.4.54%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.86%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.19%
Fidelity Stock Selector Small Cap Fund2.29%
iShares Russell 2000 ETF2.08%
Fidelity Series Small Cap Opportunities Fund1.31%
Fidelity Advisor Biotechnology Fund1.21%
Strategic Advisers Fidelity U.S. Total Stock Fund1.09%
VANGUARD EXTENDED MARKET INDEX FUND1.02%
AB Small Cap Growth Portfolio0.93%
T. Rowe Price Health Sciences Fund, Inc.0.90%

OakChart. AVTX. Cached 15 minutes.